# Restless Legs Syndrome (RLS) Treatment Guideline
**Developed by**: American Academy of Neurology
**Description**:
This corresponds to the guideline published by the AAN on the management of Restless Leg Syndrome

## 1. Moderate to Severe Primary RLS
- **Consider Pharmacologic Agents:**
  - **Level A:** Pramipexole, Rotigotine, Cabergoline, Gabapentin Enacarbil
  - **Level B:** Ropinirole, Pregabalin, IV FCM
  - **Level C:** Levodopa

## 2. Targeting Sleep
- **PLMS (PLMI measured by PSG):**
  - **Level A:** Ropinirole
  - **Level B:** Pramipexole, Rotigotine, Cabergoline, Pregabalin
  - **Level C:** Levodopa

- **Objective Sleep Measures (e.g., TST, Sleep Efficiency, Sleep Latency, WASO):**
  - **Level B:** Ropinirole, Gabapentin Enacarbil, Pregabalin

- **Subjective Sleep Measures:**
  - **Level A:** Cabergoline, Gabapentin Enacarbil
  - **Level B:** Ropinirole, Pramipexole, Pregabalin
  - **Level C:** Rotigotine, Levodopa

## 3. Concomitant Psychiatric Symptoms
- **Anxiety:**
  - **Level B:** Ropinirole
- **Depression:**
  - **Level C:** Ropinirole, Pramipexole
- **Overall Mood:**
  - **Level B:** Gabapentin Enacarbil

## 4. Improving Quality of Life (QoL)
- **Level B:** Ropinirole, Pramipexole, Cabergoline, Gabapentin Enacarbil, IV FCM
- **Level C:** Rotigotine, Pregabalin

## 5. Avoiding Augmentation
- **Level C:** 
  - Pregabalin (52-week)
  - Cabergoline (30-week)

## 6. Nonresponsive to Other Treatments
- **Level C:** Prolonged-release Oxycodone/Naloxone

## 7. Nonpharmacologic Approaches
- **Level B:** Pneumatic Compression
- **Level C:** NIRS, rTMS, Vibrating Pads (subjective sleep concerns)

## 8. Serum Ferritin ≤ 75 µg/L
- **Level B:** Ferrous Sulfate with Vitamin C

## 9. Secondary RLS (ESRD on HD)
- **Level B:** Vitamin C and E supplementation
- **Level C:** Ropinirole, Levodopa, Exercise
